Hiromitsu Kumada Selected Research

adefovir dipivoxil (Hepsera)

6/2014	[Case report; Fanconi's syndrome and hypophosphatemic osteomalacia associated with adefovir dipivoxil: a case report].
6/2014	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.
3/2014	Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
2/2010	Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.
1/2008	Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
5/2007	Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine.
8/2006	Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
1/2004	Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiromitsu Kumada Research Topics

Disease

118	Hepatocellular Carcinoma (Hepatoma) 09/2022 - 01/2002
113	Infections 10/2022 - 01/2002
92	Chronic Hepatitis C 10/2022 - 01/2002
75	Fibrosis (Cirrhosis) 10/2022 - 01/2002
71	Chronic Hepatitis B 10/2022 - 01/2002
43	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 01/2002
40	Neoplasms (Cancer) 04/2022 - 01/2003
35	Hepatitis 05/2014 - 01/2002
25	Liver Diseases (Liver Disease) 10/2022 - 01/2002
24	Hepatitis B 01/2022 - 01/2002
23	Hepatitis C 07/2018 - 09/2005
20	Chronic Hepatitis (Chronic Active Hepatitis) 03/2014 - 01/2002
19	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2009
15	Anemia 01/2017 - 07/2004
13	Liver Neoplasms (Liver Cancer) 10/2022 - 07/2006
13	Carcinogenesis 01/2014 - 01/2003
11	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2009
11	Body Weight (Weight, Body) 01/2021 - 10/2007
10	Diabetes Mellitus 01/2022 - 07/2006
7	Virus Diseases (Viral Diseases) 04/2021 - 04/2003
7	Disease Progression 01/2021 - 01/2004
6	Headache (Headaches) 10/2016 - 03/2012
6	Persistent Infection 10/2013 - 05/2004
5	Insulin Resistance 01/2022 - 06/2009
5	Viremia 01/2017 - 01/2007
4	Inflammation (Inflammations) 04/2022 - 01/2012
4	Pruritus (Itching) 09/2018 - 10/2016
4	Fever (Fevers) 10/2016 - 03/2012
4	Diarrhea 04/2016 - 03/2012
4	Hypertension (High Blood Pressure) 03/2014 - 09/2009
3	Fatty Liver 04/2022 - 09/2009

Drug/Important Bio-Agent (IBA)

110	InterferonsIBA 12/2020 - 01/2002
78	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 01/2002
45	Lamivudine (Epivir)FDA Link 05/2017 - 01/2002
43	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2003
37	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2003
30	Hepatitis B e AntigensIBA 01/2022 - 01/2002
28	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 02/2002
21	daclatasvirIBA 01/2020 - 03/2012
21	Alanine Transaminase (SGPT)IBA 09/2017 - 01/2003
20	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 01/2002
19	entecavir FDA Link 01/2022 - 06/2007
17	AntigensIBA 01/2022 - 01/2002
16	Pharmaceutical PreparationsIBA 01/2022 - 11/2006
16	asunaprevirIBA 01/2020 - 03/2012
15	telaprevirIBA 02/2018 - 01/2010
14	lenvatinibIBA 09/2022 - 03/2016
14	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2020 - 01/2003
14	Transaminases (Aminotransferases)IBA 02/2015 - 01/2003
13	Amino Acids FDA Link 09/2015 - 08/2008
11	Proteins (Proteins, Gene)FDA Link 10/2022 - 03/2006
11	Serum AlbuminIBA 10/2017 - 07/2005
10	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 01/2010
10	BilirubinIBA 10/2017 - 01/2003
9	Biomarkers (Surrogate Marker)IBA 04/2022 - 12/2007
9	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 08/2008
9	miriplatinIBA 02/2018 - 01/2011
9	Interferon-alpha (Interferon Alfa)IBA 05/2014 - 02/2002
8	glecaprevir and pibrentasvirIBA 01/2020 - 01/2018
8	adefovir dipivoxil (Hepsera)FDA Link 06/2014 - 01/2004
7	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 03/2015 - 01/2006
7	Interferon-betaIBA 01/2011 - 01/2008
6	lipoarabinomannan (LAM)IBA 05/2017 - 12/2007
6	AlbuminsIBA 02/2015 - 01/2009
6	adefovirIBA 06/2014 - 01/2004
5	Tenofovir (Viread)FDA Link 12/2021 - 01/2014
5	Fetal Proteins (Fetoprotein)IBA 04/2021 - 09/2013
5	Ritonavir (Norvir)FDA Link 04/2018 - 05/2015
5	paritaprevirIBA 04/2018 - 05/2015
5	ombitasvirIBA 04/2018 - 05/2015
5	NucleosidesIBA 05/2017 - 06/2007
5	Hemoglobins (Hemoglobin)IBA 10/2016 - 11/2004
5	PlatinumIBA 03/2013 - 04/2009
4	SofosbuvirIBA 10/2022 - 01/2017
4	NucleotidesIBA 02/2022 - 09/2004
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2017
4	Sorafenib (BAY 43-9006)FDA Link 02/2021 - 09/2011
4	Glucose (Dextrose)FDA LinkGeneric 02/2020 - 06/2012
4	8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamideIBA 01/2020 - 03/2017
4	grazoprevirIBA 01/2020 - 04/2017
4	elbasvirIBA 01/2020 - 04/2017
4	P-300IBA 08/2019 - 01/2018
4	SimeprevirIBA 01/2017 - 05/2014
4	Branched-Chain Amino AcidsIBA 05/2013 - 07/2005
4	Aspartic Acid (Aspartate)FDA Link 04/2010 - 05/2004
3	Cell-Free Nucleic AcidsIBA 04/2022 - 02/2020
3	Tumor Biomarkers (Tumor Markers)IBA 04/2022 - 01/2008
3	CanagliflozinIBA 01/2022 - 05/2019
3	Surface Antigens (Surface Antigen)IBA 01/2022 - 12/2002
3	Circular DNAIBA 01/2022 - 01/2009
3	Peptides (Polypeptides)IBA 09/2021 - 09/2008
3	TransferasesIBA 04/2021 - 08/2004

Therapy/Procedure

184	Therapeutics 10/2022 - 01/2002
19	Radiofrequency Ablation 02/2019 - 01/2002
10	Drug Tapering 01/2017 - 07/2004
9	Hepatectomy 10/2020 - 12/2013
7	Drug Therapy (Chemotherapy) 10/2014 - 11/2011
6	Aftercare (After-Treatment) 02/2021 - 12/2006
5	Retreatment 03/2019 - 04/2003
4	Duration of Therapy 01/2018 - 01/2010